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Objectives This study questioned whether transaxillary transcatheter aortic valve implantation
(TAVI) is feasible as a true percutaneous approach using percutaneous closure devices.
Background Transaxillary TAVI is gaining increasing acceptance as an alternative to the transfemo-
ral route; however, the access has always been done via surgical cutdown so far.
Methods Between August 2010 and September 2011, a total of 24 high-risk patients with severe
aortic valvular stenosis underwent a percutaneous TAVI procedure by direct puncture of the axillary
artery without surgical cutdown. For safety reasons and as a target for the puncture, a wire was ad-
vanced via the ipsilateral brachial artery. Moreover, a balloon was placed into the subclavian artery
via the femoral artery for temporary vessel blockade before percutaneous vessel closure. Vascular
closure was performed using either the ProStar XL system (Abbott Vascular Devices, Redwood City,
California) or 2 ProGlide systems (Abbott Vascular Devices).
Results The true percutaneous approach was successfully completed in all patients (14 left and 8
right axillary artery cases). Overall mortality at 30 days was 8.3%. Acute vascular closure device suc-
cess was achieved in 17 patients (71%). Vascular closure device success rate was 100% for the Pro-
Glide device and 37% for the ProStar device, respectively. Seven patients (29%) with failing closure
devices were treated by endovascular stent graft implantation without the need for surgical repair.
For the last 12 treated patients, direct closure was achieved in 11 patients.
Conclusions Direct puncture of the axillary artery for TAVI is feasible and safe if a wire is
placed into the subclavian artery via the ipsilateral brachial artery. (J Am Coll Cardiol Intv
2012;5:477–86) © 2012 by the American College of Cardiology Foundation
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478In 2002, transcatheter aortic valve implantation (TAVI)
was successfully introduced as a new treatment option for
aortic valvular stenosis (1). Since then, rapidly rising
implantation numbers (25,000) have proven the feasi-
bility and safety of this technology. Nowadays, TAVI
may be considered as a better alternative to surgical aortic
valve replacement in high-risk patients. When TAVI was
in its infancy, it was still necessary to surgically expose the
arterial access vessels under general anesthesia to accommodate
See page 487
the large introducers of the first-generation devices (1–4).
Currently, 2 Conformité Européenne (CE)-marked de-
vices for transfemoral TAVI—Sapien XT bioprosthesis
(Edwards Lifesciences, Irvine, California) and Medtronic
CoreValve System (Medtronic, Minneapolis, Minnesota)—
are approved for TAVI via sheathes with an 18- or 19-F
diameter. The Sapien prosthesis can also be implanted via
a transapical approach (5). The major goal of creating
ower-profile devices was to obtain a true percutaneous
ccess in conjunction with local anesthesia (an advantage
over the transapical access with
its need for general anesthesia) and
the use of vascular closure devices,
thereby reducing the high vascular
complication rates and improving
patient outcomes (6,7). In this
regard, the recently published
PARTNER (Placement of Aortic
Transcatheter Valve) A and B stud-
ies demonstrated major vascular
complications in 11% and 16.2%, respectively. The total
number of in-hospital deaths in both randomized treat-
ment arms was increased 3-fold (36% vs. 10.3%) in
patients with vascular complications compared with those
without vascular complications (8,9). Over the last 3
years, alternative access sites, such as the transaxillary
(10,11) or the transaortic (12) approach, have been
introduced. For the transaxillary approach, mainly the
Medtronic CoreValve and only a few Sapien XT valves
have been used in the past (10,11,13,14). All these
alternative access sites have surgical exposure of the
arterial vessels under general anesthesia in common.
Safety and feasibility of the transaxillary approach using a
surgical cutdown has been repeatedly demonstrated
(10,11).
The present paper describes for the first time, to our
knowledge, a new access site technique for direct percuta-
neous puncture of the axillary artery in a series of 24
consecutive patients for TAVI, not suitable for the trans-
femoral approach. Puncture technique, site visualization,
Abbreviations
and Acronyms
PTA  percutaneous
transluminal angioplasty
TAVI  transcatheter aortic
valve implantation
VARC  Valve Academic
Research Consortiumand closure technique in addition to several treatment aoptions for the management of vascular complications are
outlined in the following text.
Methods
Between August 2010 and September 2011, a total of 24
patients with severe aortic stenosis underwent percutaneous
transaxillary TAVI (self-expandable devices) at our institu-
tion (12.1% of 385 TAVI procedures). All patients had
symptomatic severe aortic valvular stenosis with an in-
creased operative risk (logistic EuroSCORE 20% or a
Society of Thoracic Surgeons [STS] score 10%—or other
risk factors for surgical aortic valve replacement, such as
porcelain aorta, cirrhosis of the liver, previous radiation
treatment of the chest), and all patients were identified as
not suitable for the transfemoral approach because of severe
peripheral artery disease (severe calcification, significant
stenosis/occlusions, or severe vessel tortuosity) as assessed by
angiography or multislice computed tomography. Angiog-
raphy of the subclavian arteries with a graduated pigtail
catheter was performed to confirm a sufficient access path
for percutaneous transaxillary TAVI. Moreover, a precise
evaluation of the aortic annulus (size, morphology, amount
of calcification) was carried out via transesophageal echo-
cardiography and angiography using a graduated pigtail
catheter. An annulus size between 19 and 27 mm was
accepted for implantation of a CoreValve prosthesis (26 or
29 mm, Edwards Lifesciences). Transaxillary TAVI was
performed using vascular closure devices with the intention
to start and finish TAVI solely by a percutaneous technique
without surgical exposure of the access vessel.
Procedure. Before the procedure, all patients received a
lopidogrel loading dose of 300 mg and aspirin 100 mg that
as followed by 75 mg of clopidogrel for 3 months and 100
g of aspirin indefinitely. Intravenous cefazolin was used as
ntibiotic prophylaxis. In 15 of 24 patients, percutaneous
ransaxillary TAVI was performed under general anesthesia
62.5%). The decision regarding which side was used
right or left axillary artery) was made with preference to
he artery with the least degree of calcification and
inking. Moreover, patent left internal mammary artery
rafts were considered as a relative contraindication for
AVI from the left axillary artery. Thus, 7 of 8 patients
ith left internal mammary artery grafts were treated via
he right axillary artery.
For safety reasons, a 6-F sheath (23 cm, Easy Glide,
miths Medical, Grasbrunn, Germany) was placed into the
psilateral brachial artery. Retrograde dye injection (5 to 10
l) through the sheath was used to visualize the axillary
rtery (Fig. 1A). Using fluoroscopy and a regular J-wire as a
andmark, the axillary artery was punctured below the
lavicula at a spot significantly lateral to the rib cage to avoidpneumothorax and to have the possibility for manual
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479compression of the artery (feasible in most cases) (Fig. 1B).
In addition, a second long (260 cm) regular J-wire was
advanced over the femoral artery in an antegrade manner
into the subclavian artery. For safety reasons, an appropriate
balloon (regular percutaneous transluminal angioplasty
[PTA] balloons 6 to 9 mm, 40-mm length) was inserted
over the femoral J-wire into the descending aorta and left in
place for immediate vessel blockade if needed. With in-
creasing experience (after Patient #14), a smaller wire
Figure 1. Angiography of the Subclavian Artery and Needle Puncture
in the Axillary Artery
(A) Angiography of the subclavian artery. Angiography of the access site
via a graduated pigtail catheter. (B) Needle puncture in the axillary artery.
Direct transaxillary puncture under ﬂuoroscopy with a wire as a landmark.
The wire for orientation is retrogradely inserted via the brachial artery and
kept in place as a safety net throughout the complete intervention.(0.018-inch Plywire 400 cm, OptiMed Global Care, Ettlin-gen Germany) was advanced over a regular diagnostic JR4
catheter via the brachial artery and snared down into the
femoral artery, thereby establishing an arterio-arterial
monorail access loop for endovascular stent graft implanta-
tion if needed. The length of 400 cm was chosen to have a
sufficient proportion of wire at both arterial sides (brachial
and femoral). Heparin was administered intravenously dur-
ing the procedure to achieve an activated clotting time
250 ms. After puncture of the axillary artery, a 6-F sheath
followed by a 10-F sheath was gradually introduced. Sub-
sequently, a ProStar XL 10-F device (Abbott Vascular
Devices, Redwood City, California) was used. Care was
taken to place the ProStar into the descending aorta since
the ProStar device is generally too long for placement into
the ascending aorta. With increasing experience, we mainly
used 2 ProGlide 6-F devices (Abbott Vascular Devices) as a
closure device. The ProGlide was inserted immediately after
introduction of the 6-F sheath into the axillary artery (Figs. 2A
and 2B) followed by a 10-F sheath. A stiff guidewire
(Amplatz Super Stiff ST-1, AGA Medical Corporation,
Plymouth, Minnesota) was then positioned into the left
ventricle followed by insertion of the 18-F sheath (COOK
Medical, Limerick, Ireland) (Fig. 3A). After standard val-
vuloplasty (under rapid right ventricular pacing at 180 to
200 beats/min) (Fig. 3B), TAVI was performed (Fig. 4A). After
successful valve implantation (Fig. 4B), the sheath was
carefully pulled back, and the balloon (regular PTA balloons
6 to 9 mm, 20- to 40-mm length) that was placed at the
beginning of the procedure in the descending aorta was
advanced to block the subclavian artery (Fig. 5A). After
removal of the device sheath, the sutures provided by the
ProStar XL or the 2 ProGlide systems were tied down. The
Plywire remained in situ as a safety guard to secure access
into the vessel at all times. Finally, control angiography of
the axillary artery was performed over the long sheath
previously placed in the brachial artery (Fig. 5B).
Minor vessel complications that did not affect blood flow
and blood supply were treated conservatively, that is, by
manual compression or protamine infusion, and carefully
examined 10 to 15 min later. In case of either a flow-
limiting dissection or persistent bleeding, retrograde or
antegrade treatment of the injured vessel segment was
performed using balloon dilation and/or stent implantation
(stent graft for significant bleeding/perforation, fenestrated
stent for dissection).
Follow-up. After discharge from hospital, a regular
ollow-up was carried out after 6 to 8 weeks. This follow-up
ncluded a physical examination, electrocardiography, echo-
ardiography, and laboratory tests.
esults
Patient population and anatomic data. The mean age of the
24 patients was 80.8  7.3 years. Patient characteristics are
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480summarized in Table 1. Mean transvalvular aortic pressure
gradient was 39  7.4 mm Hg, and the pre-procedural
mean calculated aortic valve area was 0.7  0.2 cm2. The
ean left ventricular ejection fraction was 42 13% (range:
15% to 70%), the mean logistic EuroSCORE was 35.3 
22.8%, and 96% of the patients were in New York Heart
Association functional class III or IV.
TAVI was performed using either the left (n 16) or the
ight (n  8) axillary artery. The mean diameters of the
rteries were 7.4  1.7 mm for the axillary artery, 7.3  0.9
Figure 2. Insertion of 2 ProGlide Devices
(A and B) Pre-closure with 2 ProGlide closure devices inserted in a 45° to
60° rotated fashion to each other. Care has to be taken that the depth of
suturing is performed in the same vessel location to prevent suture-related
stenosis or even device failure.m for the distal subclavian artery, 7.7  1.5 mm for theedial subclavian artery, and 8.6  1.1 mm for the proximal
ubclavian artery. Most of the patients had a rather straight
essel, and 4 patients had some kinking without significant
alcification. Calcification was absent in 12 patients, mild in 11
atients, and severe in 1 patient, respectively. A single patient
ad to be treated by PTA (7  40 mm Admiral, Invatec,
Figure 3. Sheath Insertion and Aortic Balloon Valvuloplasty
(A) 18-F sheath insertion. Insertion of the 18-F device sheath over a stiff
guidewire (Amplatz Superstiff ST-1) with the safety wire (0.018-inch Plywire)
kept in place. The Plywire is externalized out of the femoral artery (snare
maneuver) creating an arterio-arterial loop with an option to perform
endovascular repair from 2 sites (i.e., retrograde via the brachial artery and
antegrade via the femoral artery). (B) Aortic balloon valvuloplasty. Valvulo-
plasty in addition to injection of a small amount of dye for sizing of the
root anatomy. A percutaneous transluminal angioplasty balloon 8 mm 
40 mm is already placed into the descending aorta below the ostium of
the left subclavian artery (arrow).
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481Roncadelle, Italy) in the proximal subclavian artery for a focal
stenosis, before insertion of an 18-F sheath. Puncture was
performed into a proximal location of Segment 1 of the axillary
artery at a distance of 1.2 0.9 cm to the lateral border of the
rib cage. Care was taken to avoid puncture into side branches of
the axillary artery. In 2 patients, an expandable sheath was used
(SoloPath, Onset Medical Corporation, Irvine, California).
Procedural success and 30-day major adverse cardiac and
cerebrovascular events. Procedural device success according
Figure 4. CoreValve Implantation
(A) Insertion of the CoreValve. Start of the CoreValve implantation with
repetitive dye injection for orientation (percutaneous transluminal angio-
plasty balloon 8 mm  40 mm still placed below the ostium of the left
subclavian artery, arrow). (B). Post-procedural root angiography. Final
angiogram after successful implantation without any regurgitation.to the Valve Academic Research Consortium (VARC)criteria (15) was achieved in all but 1 patient. In this patient,
a second CoreValve prosthesis had to be implanted due to
dislocation of the first CoreValve (snare pullback due to
deep implantation) into the ascending aorta. In a second
patient, implantation success was achieved during a second
Figure 5. Balloon Occlusion and Vessel Closure
(A) Balloon occlusion during vessel closure. Balloon blockade via the femo-
ral access site after sheath removal with subsequent closure of the previ-
ously inserted sutures of the ProGlide closure devices. Both knots are
simultaneously pushed down. For safety reasons, a second balloon is
inserted via the brachial artery and kept at a distal site of the arteriotomy.
(B) Final angiography. Final retrograde angiogram after successful vessel
closure.
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482implantation attempt after complete removal and reloading
of the device was performed. Conversion to open-heart
surgery was not necessary in any patient, and no patient was
lost during TAVI. Invasive mean post-procedural aortic
transvalvular gradient was 9.4  2.4 mm Hg, and moderate
post-procedural aortic regurgitation was present in 2 (8.3%)
patients, mild in 8 (33.3%) patients, and trivial or no aortic
Table 2. Overview of Acute Vascular Closure Success (n  24)
Patient #
Access
Site
Closure
Device
Clo
Suc
1 Left ProStar Failur
2 Left ProStar Failur
3 Left ProGlide Good
4 Right ProStar Good
5 Right ProStar Bleed
6 Right ProStar Bleed
7 Right ProStar Good
8 Right ProStar Bleed
9 Left ProStar Bleed
10 Left ProGlide Good
11 Right ProStar Good
12 Left ProGlide Good
13 Left ProStar Good
14 Right ProStar Bleed
15 Left ProGlide Good
16 Left ProGlide Good
17 Left ProGlide Good
18 Left ProGlide Good
19 Left ProGlide Good
20 Left ProGlide Good
21 Left ProGlide Good
22 Left ProGlide Good
23 Right ProGlide Good
24 Left ProGlide Good
Closure device success was seen in 70.8% of the patients (ProStar 36.3%, ProGlide 100%); 29.2% of t
index procedure, but 2 patients (indicated by an asterisk) had to undergo repeat endovascular sten
Table 1. Patient Demographics
Self-Expandable Valves
(n  24)
Age, yrs 80.8 7.3
Male 66.6
Log EuroSCORE 35.3 22.8
STS score, % 15.1 4.3
Extracardiac arteriopathy 83.3
Diabetes mellitus 25
Arterial hypertension 79.2
Porcelain aorta 50
Pulmonary hypertension 45.8
Ejection fraction 42 13
Values are mean SD or %.
STS Society of Thoracic Surgeons.for ananeurysmof thebrachial artery atday8after transcatheter aortic valve implantation.Noneof thepatieregurgitation was seen in 14 patients (58.3%). Thirty-day
survival rate was 91.6%. One female patient in a rehabili-
tation center died suddenly at day 28 due to pneumonia. A
second female patient with decompensated aortic valvular
stenosis could not get weaned from the respirator despite
successful TAVI and died subsequently at day 17.
Thirty-day major adverse cardiac and cerebrovascular
events (sudden cardiac death, pericardial tamponade, fatal
major bleeding, major disabling stroke) was 0%. The inci-
dence of new-onset complete or high-grade atrioventricular
block requiring permanent pacemaker implantation was
25%. No neurological complication or other damage to the
brachial plexus was found at the site of puncture. Major
vascular complications (VARC criteria) resulting in death or
use of 4 U of blood transfusions, as well as distal
embolization with subsequent end-organ damage requiring
surgery or amputation, did not occur in any patient. Seven
of 24 patients were treated with a stent graft at the puncture
site because of persistent bleeding or failure (avulsion of the
sutures) of the vascular closure device (Table 2). A total of
3 patients received 2 U of blood transfusions, with 2 of these
patients being treated due to pre-existing anemia in con-
junction to closure device failure. Minor bleedings were
Bail-Out Treatment to
Obtain Hemostasis Final Result
Balloon-expandable stent graft Good result
Balloon-expandable stent graft Distal dissection
Balloon-expandable stent graft Good result
Balloon-expandable stent graft Good result
Balloon-expandable stent graft Good result
Self-expanding stent graft Good result
Balloon-expandable stent graft Distal dissection
ents needed a stent graft implantation. None of the patients was treated by vascular surgery at the
 2 with flow limiting dissection), and 1 patient of the latter 2 patients had to be treated surgicallysure
cess
e
e
result
result
ing
ing
result
ing
ing
result
result
result
result
ing
result
result
result
result
result
result
result
result
result
result
he pati
ting (nntswas lost during theprocedure; 2patientsdiedatdays17and28, respectively, due topneumonia.
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483successfully managed with protamine infusion and manual
compression. Thus, acute vascular closure device success was
achieved in 71%. Two patients (8.3%) had to undergo
repeated endovascular stenting due to a flow-compromising
dissection or stent graft thrombosis (at days 8 and 35 after
TAVI). In addition, 1 of these 2 cases had to undergo
surgical revision of a pseudoaneurysm of the brachial artery
at day 8 after TAVI. Overall, 6 patients of the first 16
patients were treated by stenting compared with only 1
patient of the second series of 12 patients (50% vs. 8.3%;
Table 2). The ProStar system was significantly less effective
than 2 ProGlide systems (closure success: 37% vs. 100%,
p  0.01).
Follow-up results. Overall mortality at 30 days was 8.4%. At
0 days, the mean New York Heart Association functional
lass declined from 3.2  0.4 (pre-procedural) to 2.1  0.4
at 6 weeks post-procedural (p  0.001). Follow-up echo-
ardiographic results demonstrated a sustained reduction in
ean pressure gradients (10.2  2.4 mm Hg). The esti-
ated aortic valve area showed a persistent improvement
ith the self-expandable bioprosthesis (1.9  0.3 cm2; p 
0.001 vs. before TAVI), and paravalvular aortic regurgita-
tion was present as grade 1 in 75%, as grade 1 to 2 in
20%, and as grade 2 in 5% of the patients.
Discussion
This is the first study, to our knowledge, to demonstrate
TAVI via a direct percutaneous transaxillary access.
The major findings of the present study are first, direct
puncture of the axillary artery for TAVI is feasible and safe
in patients not suitable for the transfemoral approach, with
technical success in all patients. Second, the ProGlide
system seems to be more effective for closure of the axillary
artery puncture site than the ProStar XL system. Third, if
failure of vessel closure devices occurs, access to the axillary
artery puncture site can be provided over the ipsilateral
brachial artery or the femoral artery for balloon occlusion or
stent graft implantation.
The biggest concern for direct puncture of the transaxil-
lary artery is the risk of major bleeding and dissection. The
direct puncture of the axillary artery was used in the present
study to avoid a surgical cutdown. Puncture was facilitated
by angiography via the brachial artery to identify the right
spot and by placement of a wire into the axillary artery,
which served as a landmark. Either ProStar or ProGlide was
used as “pre-closure” technique. Both vascular closure de-
vices are the most commonly used suture-based systems to
close the arteriotomies at the femoral site after percutaneous
TAVI without surgical cutdown. To our knowledge, the use
of vascular closure devices at the axillary or subclavian artery
has not been described in the literature so far.
Due to the widespread confusion about the correct
anatomic terminology, it should be mentioned that evenwith a surgical cutdown to the artery, the implantation is
always done via the axillary artery and not via the subclavian
artery. By terminology, the axillary artery begins at the
lateral border of the first rib as a continuation of the
subclavian artery (Fig. 6). It changes its name to brachial
artery at the lower (inferior) border of the teres major
muscle. For a more detailed description, the axillary artery is
divided into 3 segments in relation to the pectoralis minor
muscle. The first segment is between the lateral border of
the first rib and the medial border of the pectoralis minor,
the second segment is behind the pectoralis minor, and the
third segment is between the lateral border of the pectoralis
minor and the inferior border of the teres major. As
described before, the puncture of the axillary artery was
performed in the area of segment 1, at a distance of 1.3 
0.7 cm to the lateral border of the rib cage, to prevent
artificial puncture into the pleural cavity. No pneumothorax
was observed in our study. In addition, care was taken to
avoid puncture into side branches (i.e., superior thoracic
artery, thoracoacromial artery, lateral thoracic artery) usually
arising from segment 2 of the axillary artery. From our
experience, artificial puncture into side branches of any
Figure 6. Anatomy of the Axillary Artery
The axillary artery begins at the lateral border of the ﬁrst rib as a continua-
tion of the subclavian artery (7). For purposes of description, it is divided
into 3 segments in relation to the pectoralis minor (pm) muscle. The punc-
ture site should address the ﬁrst segment (blue arrow), which is between
the lateral border of the ﬁrst rib and the medial border of the pm, usually.
The second segment is behind the pectoralis minor with many side
branches, and the third part is between the lateral border of the pectoralis
minor and the inferior border of the teres major (tm) muscle. The axillary
artery changes its name to brachial artery (8) at the lower (inferior) border
of the tm muscle. Side branches of the axillary artery: (1) superior thoracic
artery; (2) thoracoacromial artery; (3) lateral thoracic artery; (4) subscapular
artery; (5) anterior humeral circumﬂex artery; and (6) posterior humeral cir-
cumﬂex artery.
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484vessel is a frequent cause of closure device failure or
significant bleeding, especially at the femoral anatomic site
during transfemoral TAVI. In the present study, the inci-
dence of major vascular complications according to VARC
was 0%. However, minor complications (VARC definition)
necessitating stent graft implantation occurred in 29.2%. It
is noteworthy to mention that the threshold for stent graft
implantation was rather low, because compression treat-
ment may be difficult (especially in obese patients) in this
particular anatomic region (as opposed to the common
femoral artery).
Using 2 ProGlide systems was significantly more effective
compared with the ProStar system (closure success: 100%
vs. 37%). Similar differences in the efficacy between both
closure devices have not been observed for the femoral
approach. A possible explanation might be the different
anatomic structure of the vessel wall of the subclavian/
axillary artery compared with the femoral artery. As shown
in the vessel specimens (Fig. 7), the subclavian/axillary
arteries are of the elastic type with multiple layers of elastic
fibers in the media. By contrast, the femoral artery is of the
muscular type with a thicker media, mainly containing
smooth muscle cells (with only a few strands of elastic
Figure 7. Histological Sections
(A) Subclavian artery and (B) femoral artery. These histological sections staine
with the 1-mm scales indicated. The media of the subclavian artery contains a
elastic ﬁbers.fibers) between the internal and external elastic laminae
(Fig. 7). Furthermore, the adventitia of the femoral artery is
more fibrous and thicker than that of the subclavian artery.
These differences in the histological structure may have an
impact on the efficacy of the 2 vascular closure devices that
were used in our study.
In 7 of 24 patients, we were not able to sufficiently close
the puncture site with the used pre-closure technique,
necessitating implantation of stent grafts. Interestingly, all
failures with vascular closure devices were observed with
ProStar. There are several possible explanations for this
observation. As mentioned earlier, the elasticity of the
axillary artery might impinge on the methodological and
mechanical work mode of the ProStar device. For compar-
ison, the ProGlide is operated with 2 needles that are
deployed within the tissue track and directed toward the feet
of the closure device, which are placed at the inner wall of
the artery (16). The feet capture the needles, thereby
creating a suture loop leaving behind 2 suture tails (closure
is usually achieved with 2 ProGlide) (17). By contrast, the
ProStar uses 4 needles simultaneously (2 sutures) directed
outward from within the arterial lumen. By pulling on the
device handle, the needles are pulled through the arterial
he Gallego technique show the subclavian and femoral arteries of 2 cases
nt elastic ﬁbers (wavy red lines), whereas that of the femoral artery lacksd by t
bunda
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485wall, leaving behind 4 suture ends (2 sutures) (17). Besides
these methodological differences, the ProStar is much stiffer
compared with the ProGlide, thereby possibly distorting the
vessel wall more (a thinner vessel compared with the femoral
artery) with a higher likelihood of subsequent trauma. In
addition, the working angle was sometimes very steep (deep
anatomic location of the axillary artery), again hampering
correct needle placement of the ProStar device. Thus, we had
4 complete avulsions of the sutures and 3 persistent bleedings
despite successful knot delivery toward the arteriotomy.
The considerable low incidence of severe bleeding (4 U
of blood; n  0) in our series is most likely related to a
procedural strategy that anticipated vessel injury/closure
device failure even before puncture of the axillary artery.
With a wire and a blocking balloon in place (either via the
distal brachial access point or the femoral artery), temporary
vessel occlusion as well as stent graft implantation can be
performed whenever necessary. Moreover, with a blocking
balloon in place, vessel closure can be performed without
haste under dry conditions. None of the patients developed
significant hematoma, and the cosmetic result in all patients
was excellent (Fig. 8). In addition, we did not observe a
single neurological complication, despite the close proximity
of the brachial plexus at the area of the puncture site.
The rate of 29.2% minor vascular complication (despite
0% major vascular complication) may be considered unac-
ceptably high, but compared with the transfemoral approach
with reported major vascular complications in the range of
7.3% to 22.9% (Edwards Sapien valves) and between 3.9%
and 16.9% (Medtronic CoreValve—definition of vascular
complication between various publications) (10,18,19), the
transcutaneous transaxillary TAVI seems to be a reasonable
Figure 8. Photography After Transaxillary TAVI
Final small skin incision with only a small hematoma after successful trans-
cutaneous transcatheter aortic valve implantation (TAVI) (“The Hamburg
Sankt George Approach”).alternative. With regard to the high incidence of stenting
due to vascular closure device failure, endovascular treat-
ment of the subclavian/axillary artery with stents has been
proven to be feasible and safe in numerous studies, with an
immediate success rate of 93% to 100% (20–23). In addition,
due to the high-flow state of the supra-aortic vessels, long-term
primary patency has been shown to range between 72% and
93%, with a secondary patency of up to 96% (24). Thus, the
risk and benefit of a direct percutaneous puncture of the axillary
artery for TAVI seems to be acceptable. Nevertheless, the risk
of injury to the internal thoracic artery remains an issue that
may even exclude patients from a transaxillary approach (rela-
tive contraindication), but due to the very lateral puncture, we
did not see any compromise of the internal thoracic artery in
3 of 7 cases where we had to perform endovascular stenting
(3 left, 4 right).
Finally, there is usually a certain stepdown by 1 to 2 mm
in vessel diameter from the subclavian artery to the axillary
artery, making questionable the concept of balloon-
expandable stent grafts at that anatomic site. In fact, 2
patients experienced a distal dissection that occurred several
days later, most probably due to a laterally oversized stent.
Since the subclavian/axillary artery is particularly prone to
dissections, a careful matching of the stent to the vessel size
is needed. Thus, the use of self-expanding stents seems to be
advisable. The major disadvantage of self-expandable stent
grafts is the relatively large sheath size that has to be used
(usually 8- to 10-F compared with 6- to 7-F for balloon-
expandable stent grafts). To overcome this limitation, an
antegrade approach, such as the femoral approach, is usually
needed since 8- to 10-F should not be introduced into the
brachial artery. Due to the availability of 2 access sites over
a single arterio-arterial looped long wire, temporary vessel
occlusion can be additionally performed via the brachial
artery (rendezvous approach) with subsequent antegrade
endovascular stenting under nicely controlled conditions. If
anything fails, the vascular surgeon can be called to perform
surgical repair without significant bleeding, which was never
necessary in this study.
Summary. Increasing experience with vascular closure de-
vices in addition to practical knowledge for vascular com-
plication management led us as the first group to develop a
new and truly percutaneous approach for transaxillary TAVI
(“the Hamburg Sankt Georg approach”). As demonstrated
in a series of 24 patients, using vascular closure devices,
transaxillary TAVI can be carried out in a true percutaneous
fashion and with only local anesthesia in a considerable
proportion. The key factor to assure access to possible
life-threatening vessel injuries is to place a long “safety-net”-
wire from a distal access point (i.e., brachial artery) into the
subclavian artery before direct puncture, pre-closure, and
device sheath insertion. The long wire should be placed in a
looped fashion from the brachial artery to the femoral artery
(or vice versa) and a noninflated balloon should be inserted
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486into the thoracic aorta and kept in this position right from
the beginning of the intervention.
Study limitations. This is a single-center study with only 24
consecutive patients demonstrating multiple different expe-
riences with this approach (learning curve, lower efficacy of
ProStar, problematic use of balloon-expandable stents, and
so on). Thus, the number is definitely too small to derive clear
conclusions for the future. Despite a 100% success rate with
ProGlide for vessel closure, the need of more dedicated
percutaneous solutions for the management of vascular access
site complications and closure device failures is needed.
Conclusions
The present study shows for the first time, to our knowl-
edge, that direct puncture of the axillary artery for TAVI is
feasible and relatively safe. Surgical cutdown of the artery
can be avoided. We therefore believe that the true percuta-
neous transaxillary “Hamburg Sankt Georg” approach has
the potential to become an alternative to the percutaneous
transfemoral approach in the future. A wire inside the subcla-
vian artery via the ipsilateral brachial and femoral artery is an
essential safety tool for immediate balloon occlusion or stent
graft implantation, in case vessel closure fails.
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